AR132041A1 - Anticuerpos cd16a y métodos de uso - Google Patents
Anticuerpos cd16a y métodos de usoInfo
- Publication number
- AR132041A1 AR132041A1 ARP240100529A ARP240100529A AR132041A1 AR 132041 A1 AR132041 A1 AR 132041A1 AR P240100529 A ARP240100529 A AR P240100529A AR P240100529 A ARP240100529 A AR P240100529A AR 132041 A1 AR132041 A1 AR 132041A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- binding fragment
- cd16a
- antibody
- construct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno que se unen específicamente a CD16A humana. Reivindicación 1: Un anticuerpo anti-CD16A o fragmento de unión a antígeno del mismo, que comprende un anticuerpo o fragmento de unión del mismo que se une específicamente a CD16A humana. Reivindicación 13: Un constructo que comprende el anticuerpo anti-CD16A o el fragmento de unión a antígeno del mismo de cualquiera de las reivindicaciones precedentes. Reivindicación 18: Una composición farmacéutica que comprende el anticuerpo anti-CD16A o el fragmento de unión a antígeno del mismo de cualquiera de las reivindicaciones precedentes y un portador farmacéuticamente aceptable. Reivindicación 19: Un ácido nucleico aislado que codifica el anticuerpo anti-CD16A o el fragmento de unión a antígeno del mismo o constructo de cualquiera de las reivindicaciones 1 - 17. Reivindicación 20: Un vector que comprende el ácido nucleico de la reivindicación 19. Reivindicación 21: Una célula huésped que comprende el ácido nucleico de la reivindicación 19 o el vector de la reivindicación 20. Reivindicación 22: Un proceso para producir un anticuerpo anti-CD16A o un fragmento de unión a antígeno del mismo que comprende cultivar la célula huésped de la reivindicación 21 y recuperar el anticuerpo o el fragmento de unión a antígeno o el constructo a partir del cultivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023079509 | 2023-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132041A1 true AR132041A1 (es) | 2025-05-21 |
Family
ID=90544635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100529A AR132041A1 (es) | 2023-03-03 | 2024-03-01 | Anticuerpos cd16a y métodos de uso |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20260008853A1 (es) |
| EP (1) | EP4676965A1 (es) |
| JP (1) | JP2026506241A (es) |
| CN (1) | CN120813603A (es) |
| AR (1) | AR132041A1 (es) |
| TW (1) | TW202436344A (es) |
| WO (1) | WO2024183636A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121758624A (zh) * | 2024-09-23 | 2026-03-31 | 北京智仁美博生物科技有限公司 | 结合人cd16和/或人cd123的多种抗体及其用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| MX385344B (es) | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. |
| DK3107938T3 (da) | 2014-05-28 | 2022-07-11 | Zymeworks Inc | Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf |
| CN108283001B (zh) | 2015-10-08 | 2022-08-19 | 酵活有限公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
| US20240101677A1 (en) * | 2021-01-27 | 2024-03-28 | Innovent Biologics (Suzhou) Co., Ltd. | Single-domain antibody against cd16a and use thereof |
| JP2024524378A (ja) * | 2021-06-29 | 2024-07-05 | 山▲東▼先声生物制▲薬▼有限公司 | Cd16抗体及びその応用 |
| US20240352128A1 (en) * | 2021-08-25 | 2024-10-24 | Nanjing GenScript Biotech Co., Ltd. | ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a |
-
2024
- 2024-03-01 EP EP24714767.1A patent/EP4676965A1/en active Pending
- 2024-03-01 TW TW113107461A patent/TW202436344A/zh unknown
- 2024-03-01 JP JP2025550938A patent/JP2026506241A/ja active Pending
- 2024-03-01 CN CN202480016076.5A patent/CN120813603A/zh active Pending
- 2024-03-01 WO PCT/CN2024/079594 patent/WO2024183636A1/en not_active Ceased
- 2024-03-01 AR ARP240100529A patent/AR132041A1/es unknown
-
2025
- 2025-09-02 US US19/315,937 patent/US20260008853A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026506241A (ja) | 2026-02-20 |
| CN120813603A (zh) | 2025-10-17 |
| WO2024183636A1 (en) | 2024-09-12 |
| TW202436344A (zh) | 2024-09-16 |
| US20260008853A1 (en) | 2026-01-08 |
| EP4676965A1 (en) | 2026-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| RU2013111533A (ru) | Способы получения мультиспецифичных и мультивалентных антител | |
| BR112023020371A2 (pt) | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| AR058955A1 (es) | Inmunglobulinas que se unen a interleuquina 13 | |
| PE20240589A1 (es) | ANTICUERPOS CD1a Y SU USO | |
| SA522440646B1 (ar) | أجسام مضادة ترتبط بـ siglec15 واستخداماتها | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| MX2022014243A (es) | Proteina de union al antigeno st2. | |
| AR125074A1 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| AR131527A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| BR112021017860A2 (pt) | Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica | |
| AR132064A1 (es) | Anticuerpos anti-cldn6 y métodos de uso | |
| AR132159A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| PE20251175A1 (es) | Anticuerpos anti-bmp9 y metodos de uso de los mismos | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR132063A1 (es) | Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso | |
| AR130641A1 (es) | Anticuerpos anti-cd28 | |
| AR130129A1 (es) | Constructos de unión a cd98 para tratar tumores cerebrales | |
| MX2024006969A (es) | Anticuerpos dlk1 y metodos de tratamiento del cancer. | |
| AR127445A1 (es) | Anticuerpos de unión a claudina 18.2 y fragmentos de estos |